

P1479

Abstract (poster session)

**Activity of tigecycline and comparators against multidrug-resistant Gram-negative bacteria in Africa-Middle East: TEST 2006-2010**

M. Renteria\*, S. Bouchillon, D. Hoban, M. Hackel, B. Johnson, N. Raghuvir (Schaumburg, Collegeville, US)

Background: Reduced treatment options for multi-drug resistant (MDR) gram negative bacteria are a major cause of mortality for patients with nosocomial infections. The global Tigecycline Evaluation and Surveillance Trial (TEST) evaluated the activity of tigecycline and comparators against MDR *Acinetobacter baumannii*, *Enterobacter aerogenes* and *E. cloacae* from Latin America during 2006-2010. Methods: A total of 851 clinical isolates of MDR *A. baumannii*, *E. aerogenes* and *E. cloacae* were collected from multiple infection sources in Africa-Middle East during 2006-2010. MICs and % Sus were determined at each site using prepared broth microdilution panels following CLSI guidelines. MDR isolates were defined as those resistant to three or more antimicrobial drug classes. Results: The MIC<sub>50</sub> and MIC<sub>90</sub> in mcg/ml, for tigecycline and selected comparators are shown in the following table of MDR species: TABLE Conclusions: In vitro susceptibility data shows tigecycline and levofloxacin with the lowest MIC<sub>90</sub> values against MDR *A. baumannii*, with an MIC<sub>90</sub> of 2 mcg/ml for tigecycline and an MIC<sub>90</sub> of >8 mcg/ml for levofloxacin. Against *Enterobacter* spp., meropenem exhibited the lowest MIC<sub>90</sub> (1 mcg/ml for *E. aerogenes* and 2 mcg/ml for *E. cloacae*), followed by tigecycline with an MIC<sub>90</sub> of 4 mg/ml. These findings suggest that tigecycline may be a potential therapeutic option in the treatment of selected MDR gram-negative bacteria in Africa-Middle East.

Drug	<i>A. baumannii</i> (N=464)			<i>E. aerogenes</i> (N=79)			<i>E. cloacae</i> (N=308)		
	MIC <sub>50</sub>	MIC <sub>90</sub>	%S	MIC <sub>50</sub>	MIC <sub>90</sub>	%S	MIC <sub>50</sub>	MIC <sub>90</sub>	%S
Tigecycline	1	2	na	1	4	84.8	1	4	89.9
Cefepim e	32	> 32	8.4	=0.5	16	88.6	4	> 32	73.7
Ceftazidime	> 16	> 16	4.1	> 16	> 16	na	> 16	> 16	na
Levofloxacin	8	> 8	8.6	0.25	> 8	68.4	0.5	> 8	72.4
Meropenem	> 16	> 16	15	=0.06	1	94.7	0.12	2	89.1
Minocycline	4	16	55.6	4	> 16	51.9	8	> 16	41.2
PipTazo	> 128	> 128	1.3	64	> 128	30.4	32	> 128	37.3